Biotech ETFs Reeling in Longest Sector Selloff in Two Decades


Biotech ETFs that track smaller biotech companies also got the worst of the selling. Since June 6, the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC), which tracks potential up-and-coming biotechnology companies that are in the clinical trials stage, fell 14.4%. The ALPS Medical Breakthroughs ETF (NYSEArca: SBIO), which focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III U.S. FDA clinical trials, declined 12.2%.

BBC includes a 1.3% in IMGN. SBIO holds 0.07% in INFI.

Related: 17 Healthcare ETFs Investors Should Check Up On

Meanwhile, other segments of the healthcare industry have held up over the same period. For instance, the iShares U.S. Healthcare Providers ETF (NYSEArca: IHF), which follows companies that provide health insurance, diagnostics and specialized treatments, dipped 0.6% and the broader First Trust Health Care AlphaDEX Fund (NYSEArca: FXH), which tracks a smart-beta health care sector indexing methodology, dropped 1.0%.

For more information on the biotech sector, visit our biotechnology category.

iShares Nasdaq Biotechnology ETF